In this review:
Malnutrition and liver transplant outcomes
Long-term course of histologically advanced NAFLD
Glecaprevir/pibrentasvir in treatment-naive HCV genotype 3
Glecaprevir/pibrentasvir in chronic genotype 1-6 HCV with compensated cirrhosis
Sofosbuvir/velpatasvir/voxilaprevir in NS5A-inhibitor-experienced HCV
Ledipasvir/sofosbuvir in genotype 1 HCV with severe renal impairment
Direct-acting antivirals and HCC risk
MRCP predicts disease progression in PSC
Nivolumab in sorafenib-naive and -experienced HCC
Myrcludex B + tenofovir in chronic HBV/HDV co-infection
Please login below to download this issue (PDF)